Author/Authors :
Yen-Ting Chen، نويسنده , , Thomas D. Bannister، نويسنده , , Amiee Weiser، نويسنده , , Evelyn Griffin، نويسنده , , Li Lin، نويسنده , , Claudia Ruiz، نويسنده , , Michael D. Cameron، نويسنده , , Stephan Schürer، نويسنده , , Derek Duckett، نويسنده , , Thomas Schroter، نويسنده , , Philip LoGrasso، نويسنده , , Yangbo Feng، نويسنده ,
Abstract :
Inhibition of Rho kinase (ROCK) is an attractive strategy for the treatment of diseases such as hypertension, glaucoma, and cancer. Here we report chroman-3-amides as highly potent ROCK inhibitors with sufficient kinase selectivity, excellent cell activity, good microsomal stability, and desirable pharmacokinetic properties for study as potential therapeutic agents.
Keywords :
rock , ROCK-II , Glaucoma , kinase , Chromans , Rho kinase
